当前位置:首页 - 行情中心 - 微电生理(688351) - 财务分析 - 利润表

微电生理

(688351)

  

流通市值:79.81亿  总市值:79.81亿
流通股本:4.71亿   总股本:4.71亿

利润表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、营业总收入275,244,341.46125,927,267.47464,531,979.47336,400,837.87
  营业收入275,244,341.46125,927,267.47464,531,979.47336,400,837.87
二、营业总成本267,791,120.28121,957,741.76436,363,192.99308,654,820.49
  营业成本121,743,076.2455,664,256.8195,221,050.33137,611,777.99
  税金及附加2,162,389.221,282,977.723,526,846.152,846,155.77
  销售费用81,346,118.3234,711,508.26133,219,020.295,311,346.03
  管理费用19,929,764.389,414,188.8443,276,172.5331,323,786.18
  研发费用36,638,191.517,844,474.0964,081,885.0745,759,833.28
  财务费用5,971,580.623,040,336.05-2,961,781.29-4,198,078.76
  其中:利息费用108,705.0356,923.68300,075.96267,626.67
  其中:利息收入1,420,883.72883,823.714,062,066.253,375,213.61
三、其他经营收益
  加:公允价值变动收益3,504,976.781,771,448.117,528,763.665,576,400
  加:投资收益23,605,020.2622,533,771.547,860,780.255,752,496.14
  资产处置收益-30,791.1-49,164.17712,121.36712,121.36
  资产减值损失(新)-2,693,036.7-600,600.72-3,390,007.88-2,615,676.27
  信用减值损失(新)-1,124,752.77-667,813.14-1,213,967.77-1,310,636.3
  其他收益9,796,473.462,168,815.2713,817,066.728,391,284.05
四、营业利润40,511,111.1129,125,982.653,483,542.8244,252,006.36
  加:营业外收入886.2-36,394.149,347.02
  减:营业外支出500,000-886.22,177,048.412,163,300
五、利润总额40,011,997.3129,126,868.851,342,888.5542,098,053.38
  减:所得税费用-73,270.4242,162.59260,588.31177,495.24
六、净利润40,085,267.7329,084,706.2151,082,300.2441,920,558.14
(一)按经营持续性分类
  持续经营净利润40,085,267.7329,084,706.2151,082,300.2441,920,558.14
(二)按所有权归属分类
  归属于母公司股东的净利润40,085,267.7329,084,706.2151,082,300.2441,920,558.14
  扣除非经常损益后的净利润3,162,956.532,298,227.6823,588,628.1624,066,000.8
七、每股收益
  (一)基本每股收益0.090.060.110.09
  (二)稀释每股收益0.090.060.110.09
八、其他综合收益-11,045,551.69-8,526,714.755,041,778.74,045,296.27
  归属于母公司股东的其他综合收益-11,045,551.69-8,526,714.755,041,778.74,045,296.27
九、综合收益总额29,039,716.0420,557,991.4656,124,078.9445,965,854.41
  归属于母公司股东的综合收益总额29,039,716.0420,557,991.4656,124,078.9445,965,854.41
公告日期2026-08-282026-04-302026-03-312025-10-28
审计意见(境内)标准无保留意见
TOP↑